• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > GlaxoSmithKline > October 31, 2011

      World's First Malaria Vaccine Shows Promising Results

      Malaria is a life-threatening disease that kills nearly 800,000 people a year worldwide, most of whom are children in Africa. GlaxoSmithKline, one of the world’s leading vaccine companies, has developed a new malaria vaccine known as RTS,S or Mosquirix that could reduce the risk of malaria infection. In a major clinical trial, the world’s first malaria vaccine was found to halve the risk of malaria in 5- to 17-month-old infants in Africa, where thousands of children die from malaria each year.

      Preliminary results of the trial have shown that the initial malaria vaccine shots reduced the risk of children developing clinical malaria and severe malaria by 56 percent and 47 percent, respectively. The makers of the experimental vaccine are happy with the outcome of first shots of the vaccine. The chief executive of GlaxoSmithKline, Andrew Witty, said that further efforts would be taken to increase the efficacy of the vaccine. He also said that GSK is committed to pricing the vaccine as low as possible.

      Malaria is an endemic disease in around 100 countries. The RTS,S vaccine candidate is the first one of its kind against a parasite-borne infection and it took more than 25 years to develop—a significant milestone in the fight against malaria, a deadly disease. The trial is still going on and the results of the vaccine in 6- to 12-week-old infants are expected by the end of 2012. GSK hopes that the RTS,S vaccine could be made available for commercial use in 2015 if further results are positive.


      Share this Article!

    Back to top^